Patient-Derived Xenograft/PDX Model Market

Patient-Derived Xenograft/PDX Model Market by Type (Mice, Rat), Implantation Method (Subcutaneous, Orthotopic), Tumor Type (Respiratory, Hematological), Application (Drug Development, Biobanks), End User (Pharma, Biotech, CROs) - Global Forecast to 2028

Report Code: BT 5576 Aug, 2023, by marketsandmarkets.com

The global PDX model market in terms of revenue was estimated to be worth $426 million in 2023 and is poised to reach $839 million by 2028, growing at a CAGR of 14.5% from 2023 to 2028. The new research study consists of an industry trend analysis of the market. The new research study consists of industry trends, pricing analysis, patent analysis, conference and webinar materials, key stakeholders, and buying behaviour in the market. The key factors driving the growth of the global patient-derived xenografts model market are the growing demand for personalized medicine, technological advancements in PDX technology, and rising investments in cancer research. However, the FDA’s announcement to discontinue animal models for clinical trials is expected to restrain market growth to a certain extent.

Attractive Opportunities in the patient-derived xenografts/ PDX models market

Patient-Derived Xenograft/PDX Model Market

To know about the assumptions considered for the study, Request for Free Sample Report

Patient-Derived Xenograft/PDX Model Market

PDX Model Market Dynamics

DRIVER: Growing demand for personalized medicine

Personalized medicine aims to tailor medical treatments to individual patients based on their unique genetic and molecular profiles, enhancing treatment efficacy and minimizing adverse effects. PDX models have emerged as pivotal tools in this paradigm shift, providing a bridge between preclinical research and clinical application. PDX models allow researchers to replicate patient-specific tumors in an in vivo context, enabling the testing of various therapies for personalized treatment strategies. Their ability to maintain the heterogeneity and microenvironment of tumors closely mimics real-world patient scenarios. As a result, pharmaceutical companies and research institutions are increasingly adopting PDX models to develop and validate personalized treatment approaches.

RESTRAINT: FDA’s announcement to discontinue animal models for clinical trials

In December 2022, USFDA announced the dispensing of the prerequisite for animal testing in the initial phases of pharmaceutical development, marking a pivotal juncture in the regulatory framework governing drug research and innovation. This strategic shift stems from an amplified acknowledgment of the inherent limitations inherent in conventional animal models and the overarching drive to contemporize drug development paradigms. Although this shift is poised to herald constructive changes within the industry, it also holds the potential to engender certain challenges, particularly within the domain of the patient-derived xenograft (PDX) model market.

OPPORTUNITY: Emergence of CRISPR in biomedical research

CRISPR tool enables precise and efficient genetic modifications in PDX models, allowing researchers to create more accurate and sophisticated models that closely mimic human disease conditions. CRISPR-mediated modifications enable the introduction of specific mutations, deletions, or insertions into PDX models, replicating patient-specific genetic alterations observed in various diseases, including cancer. This capability not only enhances the authenticity of PDX models but also facilitates the investigation of genetic drivers and disease mechanisms. By utilizing CRISPR-edited PDX models, researchers can better dissect the role of specific genes and pathways in tumor growth, progression, and treatment responses, thereby providing valuable insights into personalized therapeutic strategies.

CHALLENGE: Development of alternative animal testing methods

Alternative methods, like in vitro cell culture models, organoids, and microphysiological systems, offer advantages such as reduced animal usage, cost-effectiveness, and high-throughput capabilities. This trend aligns with increasing ethical and regulatory concerns regarding traditional animal testing. As the pharmaceutical and research industries pivot toward more humane and predictive models, the adoption of these alternatives poses a potential threat to the demand for PDX models. Additionally, these alternatives offer faster results, allowing for quicker decision-making in drug development pipelines. This dynamic landscape necessitates strategic adaptations by PDX model providers to maintain their market relevance.

Patient Derived Xenograft / PDX Model Market Ecosystem:

Prominent companies in the market include well-established, financially stable manufacturers of patient-derived xenografts/ PDX model products. These companies have been operating in the market for several years and possess diversified, state-of-the-art technologies, product portfolios, and strong global sales and marketing networks. Prominent companies in this market include JSR Corporation (Japan), Wuxi Apptec (China), The Jackson Laboratory (US), Charles River Laboratories International, Inc. (US), Taconic Biosciences, Inc. (US), Oncodesign Precision Medicine (France), Inotiv, Inc. (US), Pharmatest Services (Finland), Hera BioLabs (US),  EPO Berlin-Buch GmbH (Germany), Xentech (France), Urosphere (France), Altogen Labs (US), Abnova Corporation (US), Genesis Biotechnology Group (US), Biocytogen Pharmaceuticals Co., Ltd. (China), Creative Animodel (US), BioDuro-Sundia (US), Aragen Life Sciences (India), Shanghai LIDE Biotech Co., Ltd. (China), Certis Oncology Solutions (US), InnoSer (Netherlands), IVRS AB (Sweden), Beijing IDMO Co. Ltd. (China), and Shanghai Chempartner Co. Ltd. (China).

Patient-Derived Xenograft/PDX Model Market Ecosystem

The subcutaneous segment accounted for the largest share of the implantation method segment in the PDX Model Industry in 2023.

Based on implantation methods, the PDX model market is categorized into subcutaneous implantation, orthotopic implantation, and other implantation methods. In 2023, the subcutaneous segment accounted for the largest share and the fastest-growing segment of the patient-derived xenografts/ PDX models market. The major drivers are propelling the accessibility and ease of Implantation of the subcutaneous method and the cost and time efficiency of the method.

The pharmaceutical and biotechnology companies segment dominated the end-user segment in the PDX model industry in 2023.

Based on the end user, the segment of the PDX model market is categorized into pharmaceutical & biotechnology companies, contract research organizations (CROs), and academic & research institutions. In 2023, the pharmaceutical and biotechnology companies segment dominated the end-user segment with the highest revenue share. Collaborative projects amongst the pharmaceutical and biotechnology companies, rising numbers of drugs in the R&D pipeline, and increasing investment in R&D are propelling the growth of the pharmaceutical and biotechnology companies market.

North America was the largest market for PDX model industry in 2023.

Geographically, the PDX model market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East Africa. The patient-derived xenografts/ PDX models market is dominated by North America in 2023, and this dominance is anticipated to continue throughout the forecast period. Factors such as extensive research focusing on novel oncology therapies, a rise in cancer prevalence, and increased adoption of personalized medicine are driving the growth of the market in North America.

Patient-Derived Xenograft/PDX Model Market by Region

To know about the assumptions considered for the study, download the pdf brochure

The prominent players in the PDX model market are JSR Corporation (Japan), Wuxi Apptec (China), The Jackson Laboratory (US), Charles River Laboratories International, Inc. (US), Taconic Biosciences, Inc. (US), Oncodesign Precision Medicine (France), Inotiv, Inc. (US), Pharmatest Services (Finland), Hera BioLabs (US),  EPO Berlin-Buch GmbH (Germany), Xentech (France), Urosphere (France), Altogen Labs (US), Abnova Corporation (US), Genesis Biotechnology Group (US), Biocytogen Pharmaceuticals Co., Ltd. (China), Creative Animodel (US), BioDuro-Sundia (US), Aragen Life Sciences (India), Shanghai LIDE Biotech Co., Ltd. (China), Certis Oncology Solutions (US), InnoSer (Netherlands), IVRS AB (Sweden), Beijing IDMO Co. Ltd. (China), and Shanghai Chempartner Co. Ltd. (China).

Scope of the PDX Model Industry

Report Metric

Details

Market Revenue in 2023

$426 million

Estimated Value by 2028

$839 million

Revenue Rate

Poised to grow at a CAGR of 14.5%

Market Driver

Growing demand for personalized medicine

Market Opportunity

Emergence of CRISPR in biomedical research

This report categorizes the PDX model market to forecast revenue and analyze trends in each of the following submarkets:

By type

  • Mouse Model
  • Rat Model

By Implantation Method

  • Subcutaneous implantation
  • Orthotopic implantation
  • Other implantation methods

By Tumor Type

  • Gastrointestinal tumor models
  • Gynecological tumor models
  • Respiratory tumor models
  • Urological tumor models
  • Hematological tumor models
  • Other tumor models

By Application

  • Preclinical drug development
  • Biomarker analysis
  • Translational research
  • Biobanking

By End Users

  • Pharmaceutical & biotechnology companies
  • Contract research organizations (CROs)
  • Academic & research institutions

By Region

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe (RoE)
  • Asia Pacific (APAC)
    • Japan
    • India
    • China
    • Australia
    • South Korea
    • Rest of Asia Pacific (RoAPAC)
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East Africa
    • Middle East
    • Africa

Recent Developments in PDX Model Industry

  • In December 2022, Crown Bioscience, Inc., a subsidiary of JSR Life Sciences, entered into a worldwide licensing agreement with ERS Genomics Limited. This agreement granted Crown Bioscience complete global access to ERS's foundational CRISPR/Cas9 patent portfolio, enabling the company to utilize CRISPR/Cas9 for genetic editing on a global scale. Under the provisions of this agreement, Crown Bioscience broadened its capabilities in genetic manipulation. The company is exploring the potential of gene editing within three-dimensional models of patient-derived tumor organoids.
  • In July 2022, GemPharmatech entered into a strategic licensing arrangement with Charles River Laboratories, Inc. This partnership entails the exclusive distribution rights for GemPharmatech's advanced NOD CRISPR Prkdc Il2r gamma (NCG) mouse lines within the North American region.
  • In November 2021, Inotiv announced the completion of the acquisition of Envigo RMS Holding Corp., a leading global provider of research models and services.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS
 
1 INTRODUCTION (Page No. - 37)
    1.1 STUDY OBJECTIVES 
    1.2 MARKET DEFINITION 
    1.3 INCLUSIONS AND EXCLUSIONS 
    1.4 STUDY SCOPE 
           1.4.1 MARKETS COVERED
           1.4.2 YEARS CONSIDERED
           1.4.3 CURRENCY CONSIDERED
    1.5 LIMITATIONS 
    1.6 STAKEHOLDERS 
    1.7 SUMMARY OF CHANGES 
    1.8 RECESSION IMPACT 
 
2 RESEARCH METHODOLOGY (Page No. - 41)
    2.1 RESEARCH DATA 
          FIGURE 1 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: RESEARCH DESIGN
           2.1.1 SECONDARY DATA
           2.1.2 PRIMARY DATA
                    FIGURE 2 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: BREAKDOWN OF PRIMARIES
    2.2 MARKET ESTIMATION METHODOLOGY 
          FIGURE 3 MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED ESTIMATION, 2023
          FIGURE 4 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET SIZE, 2023 (USD MILLION)
          FIGURE 5 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: FINAL CAGR PROJECTIONS, 2023−2028
          FIGURE 6 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: CAGR PROJECTIONS FROM ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
    2.3 DATA TRIANGULATION METHODOLOGY 
          FIGURE 7 DATA TRIANGULATION
    2.4 INDUSTRY INSIGHTS 
    2.5 RESEARCH ASSUMPTIONS 
    2.6 RECESSION IMPACT 
          TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2021–2027 (%)
          TABLE 2 US HEALTHCARE EXPENDITURE, 2019–2022 (USD MILLION)
          TABLE 3 US HEALTHCARE EXPENDITURE, 2023–2027 (USD MILLION)
 
3 EXECUTIVE SUMMARY (Page No. - 51)
    FIGURE 8 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 9 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2023 VS. 2028 (USD MILLION)
    FIGURE 10 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2023 VS. 2028 (USD MILLION)
    FIGURE 11 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION
 
4 PREMIUM INSIGHTS (Page No. - 54)
    4.1 ATTRACTIVE OPPORTUNITIES FOR PLAYERS IN PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET 
          FIGURE 12 RISING INVESTMENTS IN CANCER RESEARCH AND ADVANCEMENTS IN PDX TECHNOLOGY
    4.2 NORTH AMERICAN PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER AND COUNTRY (2023) 
          FIGURE 13 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES SEGMENT AND US TO ACCOUNT FOR LARGEST SHARES OF NORTH AMERICAN PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET IN 2023
    4.3 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION 
          FIGURE 14 PRECLINICAL DRUG DEVELOPMENT SEGMENT TO HOLD LARGEST MARKET SHARE IN 2028
 
5 MARKET OVERVIEW (Page No. - 56)
    5.1 INTRODUCTION 
    5.2 MARKET DYNAMICS 
          FIGURE 15 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
          TABLE 4 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: IMPACT ANALYSIS
           5.2.1 DRIVERS
                    5.2.1.1 Growing demand for personalized medicine
                    5.2.1.2 Technological advancements in patient-derived xenograft (PDX) models
                    5.2.1.3 Rising investments in cancer research
           5.2.2 RESTRAINTS
                    5.2.2.1 Discontinuation of animal models for clinical trials by FDA
           5.2.3 OPPORTUNITIES
                    5.2.3.1 Emergence of Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) in biomedical research
           5.2.4 CHALLENGES
                    5.2.4.1 Development of alternative animal testing methods
    5.3 TECHNOLOGY ANALYSIS 
    5.4 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 
          FIGURE 16 REVENUE SHIFT AND NEW REVENUE POCKETS FOR PLAYERS IN PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET
    5.5 SUPPLY CHAIN ANALYSIS 
          FIGURE 17 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: SUPPLY CHAIN ANALYSIS
          TABLE 5 COMPANIES AND THEIR ROLE IN PATIENT-DERIVED XENOGRAFT (PDX) MODEL SUPPLY CHAIN
    5.6 VALUE CHAIN ANALYSIS 
          FIGURE 18 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: VALUE CHAIN ANALYSIS
    5.7 ECOSYSTEM ANALYSIS 
          FIGURE 19 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: ECOSYSTEM ANALYSIS
    5.8 PORTER’S FIVE FORCES ANALYSIS 
          TABLE 6 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: PORTER’S FIVE FORCES ANALYSIS
           5.8.1 INTENSITY OF COMPETITIVE RIVALRY
           5.8.2 BARGAINING POWER OF SUPPLIERS
           5.8.3 BARGAINING POWER OF BUYERS
           5.8.4 THREAT OF SUBSTITUTES
           5.8.5 THREAT OF NEW ENTRANTS
    5.9 REGULATORY ANALYSIS 
           5.9.1 NORTH AMERICA
           5.9.2 EUROPE
           5.9.3 ASIA PACIFIC
                    5.9.3.1 China
                    5.9.3.2 Japan
                    5.9.3.3 India
                    5.9.3.4 Australia
           5.9.4 LATIN AMERICA
           5.9.5 MIDDLE EAST & AFRICA
    5.10 PRICING ANALYSIS 
           5.10.1 AVERAGE SELLING PRICE (ASP) OF PRODUCTS OFFERED BY THREE KEY PLAYERS, BY TYPE
                     TABLE 7 AVERAGE SELLING PRICE (ASP) OF PRODUCTS OFFERED BY THREE KEY PLAYERS, BY TYPE (USD)
           5.10.2 AVERAGE SELLING PRICE (ASP) TREND
    5.11 PATENT ANALYSIS 
            FIGURE 20 GRANTED PATENTS FOR PDX MODELS, 2011–2023
    5.12 KEY CONFERENCES AND EVENTS IN 2023 
            TABLE 8 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: KEY CONFERENCES AND EVENTS
    5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 
           5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS
                     FIGURE 21 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS
           5.13.2 BUYING CRITERIA
                     FIGURE 22 KEY BUYING CRITERIA FOR THREE KEY END USERS
 
6 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD (Page No. - 76)
    6.1 INTRODUCTION 
          TABLE 9 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
    6.2 SUBCUTANEOUS IMPLANTATION 
           6.2.1 FACILITATES REAL-TIME ASSESSMENT OF TUMOR GROWTH
                    TABLE 10 SUBCUTANEOUS IMPLANTATION: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 11 SUBCUTANEOUS IMPLANTATION: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 12 SUBCUTANEOUS IMPLANTATION: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 13 SUBCUTANEOUS IMPLANTATION: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 14 SUBCUTANEOUS IMPLANTATION: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 15 SUBCUTANEOUS IMPLANTATION: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.3 ORTHOTOPIC IMPLANTATION 
           6.3.1 PROVIDES HIGHLY ACCURATE REPRESENTATION OF TUMOR BEHAVIOR
                    TABLE 16 ORTHOTOPIC IMPLANTATION: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 17 ORTHOTOPIC IMPLANTATION: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 18 ORTHOTOPIC IMPLANTATION: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 19 ORTHOTOPIC IMPLANTATION: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 20 ORTHOTOPIC IMPLANTATION: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 21 ORTHOTOPIC IMPLANTATION: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    6.4 OTHERS 
          TABLE 22 OTHERS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
          TABLE 23 OTHERS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 24 OTHERS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 25 OTHERS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 26 OTHERS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
          TABLE 27 OTHERS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
 
7 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE (Page No. - 86)
    7.1 INTRODUCTION 
          TABLE 28 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
    7.2 MOUSE MODEL 
           7.2.1 GROWING USE IN CANCER RESEARCH AND DRUG DEVELOPMENT
                    TABLE 29 MOUSE MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 30 MOUSE MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 31 MOUSE MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 32 MOUSE MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 33 MOUSE MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 34 MOUSE MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    7.3 RAT MODEL 
           7.3.1 DEVELOPMENT OF NEW TECHNOLOGIES TO CREATE PDX RAT MODELS AT FASTER RATE
                    TABLE 35 RAT MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 36 RAT MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 37 RAT MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 38 RAT MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 39 RAT MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 40 RAT MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
 
8 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION (Page No. - 94)
    8.1 INTRODUCTION 
          TABLE 41 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
    8.2 PRECLINICAL DRUG DEVELOPMENT 
           8.2.1 INCREASED NUMBER OF CLINICAL TRIALS
                    TABLE 42 PRECLINICAL DRUG DEVELOPMENT: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 43 PRECLINICAL DRUG DEVELOPMENT: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 44 PRECLINICAL DRUG DEVELOPMENT: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 45 PRECLINICAL DRUG DEVELOPMENT: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 46 PRECLINICAL DRUG DEVELOPMENT: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 47 PRECLINICAL DRUG DEVELOPMENT: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    8.3 BIOMARKER ANALYSIS 
           8.3.1 GROWING DEMAND FOR BIOMARKER-BASED PERSONALIZED CANCER THERAPY
                    TABLE 48 BIOMARKER ANALYSIS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 49 BIOMARKER ANALYSIS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 50 BIOMARKER ANALYSIS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 51 BIOMARKER ANALYSIS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 52 BIOMARKER ANALYSIS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 53 BIOMARKER ANALYSIS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    8.4 TRANSLATIONAL RESEARCH 
           8.4.1 BOOMING PERSONALIZED MEDICINE MARKET
                    TABLE 54 TRANSLATIONAL RESEARCH: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 55 TRANSLATIONAL RESEARCH: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 56 TRANSLATIONAL RESEARCH: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 57 TRANSLATIONAL RESEARCH: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 58 TRANSLATIONAL RESEARCH: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 59 TRANSLATIONAL RESEARCH: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    8.5 BIOBANKS 
           8.5.1 RISING DRUG DISCOVERY AND DEVELOPMENT PROJECTS
                    TABLE 60 BIOBANKS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 61 BIOBANKS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 62 BIOBANKS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 63 BIOBANKS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 64 BIOBANKS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 65 BIOBANKS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
 
9 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER (Page No. - 106)
    9.1 INTRODUCTION 
          TABLE 66 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
    9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 
           9.2.1 ADVANCEMENTS IN TUMOR MICROENVIRONMENT RESEARCH
                    TABLE 67 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 68 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 69 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, 2021–2028 (USD MILLION)
                    TABLE 70 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 71 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 72 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    9.3 CONTRACT RESEARCH ORGANIZATIONS (CROS) 
           9.3.1 INCREASING OUTSOURCING OF DRUG DISCOVERY SERVICES
                    TABLE 73 CONTRACT RESEARCH ORGANIZATIONS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 74 CONTRACT RESEARCH ORGANIZATIONS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 75 CONTRACT RESEARCH ORGANIZATIONS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 76 CONTRACT RESEARCH ORGANIZATIONS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 77 CONTRACT RESEARCH ORGANIZATIONS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 78 CONTRACT RESEARCH ORGANIZATIONS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
    9.4 ACADEMIC & RESEARCH INSTITUTIONS 
           9.4.1 RISING R&D INVESTMENTS IN LIFE SCIENCES
                    TABLE 79 ACADEMIC & RESEARCH INSTITUTIONS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
                    TABLE 80 ACADEMIC & RESEARCH INSTITUTIONS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 81 ACADEMIC & RESEARCH INSTITUTIONS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 82 ACADEMIC & RESEARCH INSTITUTIONS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 83 ACADEMIC & RESEARCH INSTITUTIONS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                    TABLE 84 ACADEMIC & RESEARCH INSTITUTIONS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
 
10 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE (Page No. - 116)
     10.1 INTRODUCTION 
             TABLE 85 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
     10.2 GASTROINTESTINAL TUMOR MODEL 
             10.2.1 RISING DEMAND FOR EFFECTIVE CANCER THERAPEUTICS
                        TABLE 86 GASTROINTESTINAL TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 87 GASTROINTESTINAL TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 88 GASTROINTESTINAL TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 89 GASTROINTESTINAL TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 90 GASTROINTESTINAL TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 91 GASTROINTESTINAL TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
     10.3 GYNECOLOGICAL TUMOR MODEL 
             10.3.1 HIGH INCIDENCE OF TARGET CANCERS
                        TABLE 92 GYNECOLOGICAL TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 93 GYNECOLOGICAL TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 94 GYNECOLOGICAL TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 95 GYNECOLOGICAL TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 96 GYNECOLOGICAL TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 97 GYNECOLOGICAL TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
     10.4 RESPIRATORY TUMOR MODEL 
             10.4.1 INCREASING PREVALENCE OF LUNG CANCER
                        TABLE 98 RESPIRATORY TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 99 RESPIRATORY TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 100 RESPIRATORY TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 101 RESPIRATORY TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 102 RESPIRATORY TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 103 RESPIRATORY TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
     10.5 UROLOGICAL TUMOR MODEL 
             10.5.1 INCREASING FOCUS OF COMPANIES ON EXPANDING PORTFOLIO OF UROLOGICAL TUMOR MODELS
                        TABLE 104 UROLOGICAL TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 105 UROLOGICAL TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 106 UROLOGICAL TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 107 UROLOGICAL TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 108 UROLOGICAL TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 109 UROLOGICAL TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
     10.6 HEMATOLOGICAL TUMOR MODEL 
             10.6.1 ADVANCEMENTS IN TRANSLATIONAL RESEARCH AND INCREASING DEMAND FOR PERSONALIZED MEDICINE
                        TABLE 110 HEMATOLOGICAL TUMOR MODEL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
                        TABLE 111 HEMATOLOGICAL TUMOR MODEL: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 112 HEMATOLOGICAL TUMOR MODEL: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 113 HEMATOLOGICAL TUMOR MODEL: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 114 HEMATOLOGICAL TUMOR MODEL: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
                        TABLE 115 HEMATOLOGICAL TUMOR MODEL: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
     10.7 OTHERS 
             TABLE 116 OTHERS: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
             TABLE 117 OTHERS: NORTH AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 118 OTHERS: EUROPE PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 119 OTHERS: ASIA PACIFIC PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 120 OTHERS: LATIN AMERICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 121 OTHERS: MIDDLE EAST & AFRICA PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
 
11 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY REGION (Page No. - 134)
     11.1 INTRODUCTION 
             TABLE 122 PATIENT-DERIVED XENOGRAFT MODEL MARKET, BY REGION, 2021–2028 (USD MILLION)
     11.2 NORTH AMERICA 
             FIGURE 23 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET SNAPSHOT
             TABLE 123 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 124 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 125 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
             TABLE 126 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
             TABLE 127 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 128 NORTH AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.1 US
                        11.2.1.1 Growing federal research and development efforts to drive market
                                      TABLE 129 US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 130 US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
                                      TABLE 131 US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
                                      TABLE 132 US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 133 US: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.2 CANADA
                        11.2.2.1 Government-led investments in stem cell research to drive market
                                      TABLE 134 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 135 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
                                      TABLE 136 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
                                      TABLE 137 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 138 CANADA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.2.3 NORTH AMERICA: IMPACT OF RECESSION
     11.3 EUROPE 
             TABLE 139 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 140 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 141 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
             TABLE 142 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
             TABLE 143 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 144 EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.1 GERMANY
                        11.3.1.1 Increasing investments in biotechnology industry to boost market growth
                                      TABLE 145 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 146 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
                                      TABLE 147 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
                                      TABLE 148 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 149 GERMANY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.2 FRANCE
                        11.3.2.1 Increasing government funding for cancer research to support market growth
                                      TABLE 150 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 151 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
                                      TABLE 152 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
                                      TABLE 153 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 154 FRANCE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.3 UK
                        11.3.3.1 Rising focus on innovating oncology therapeutics to drive market
                                      TABLE 155 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 156 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
                                      TABLE 157 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
                                      TABLE 158 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 159 UK: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.4 ITALY
                        11.3.4.1 Growing biotechnology and pharmaceutical industries to drive market
                                      TABLE 160 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 161 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
                                      TABLE 162 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
                                      TABLE 163 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 164 ITALY: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.5 SPAIN
                        11.3.5.1 Increasing investments in clinical trials to promote market growth
                                      TABLE 165 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 166 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
                                      TABLE 167 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
                                      TABLE 168 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 169 SPAIN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.6 REST OF EUROPE
                        TABLE 170 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 171 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
                        TABLE 172 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
                        TABLE 173 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 174 REST OF EUROPE: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.3.7 EUROPE: IMPACT OF RECESSION
     11.4 ASIA PACIFIC 
             FIGURE 24 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET SNAPSHOT
             TABLE 175 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 176 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 177 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
             TABLE 178 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
             TABLE 179 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 180 ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.1 CHINA
                        11.4.1.1 Government-led fundings for clinical trials in oncology to drive market
                                      TABLE 181 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 182 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
                                      TABLE 183 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
                                      TABLE 184 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 185 CHINA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.2 JAPAN
                        11.4.2.1 Advancements in mice model technologies to drive market
                                      TABLE 186 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 187 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
                                      TABLE 188 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
                                      TABLE 189 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 190 JAPAN: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 Favorable government policies for drug development to fuel demand
                                      TABLE 191 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 192 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
                                      TABLE 193 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
                                      TABLE 194 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 195 INDIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.4 SOUTH KOREA
                        11.4.4.1 Rising investments in preclinical drug development to drive demand
                                      TABLE 196 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 197 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
                                      TABLE 198 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
                                      TABLE 199 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 200 SOUTH KOREA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.5 AUSTRALIA
                        11.4.5.1 Increased funding in clinical trials from research institutions to drive market
                                      TABLE 201 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 202 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
                                      TABLE 203 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
                                      TABLE 204 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 205 AUSTRALIA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.6 REST OF ASIA PACIFIC
                        TABLE 206 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 207 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
                        TABLE 208 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
                        TABLE 209 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 210 REST OF ASIA PACIFIC: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.4.7 ASIA PACIFIC: IMPACT OF RECESSION
     11.5 LATIN AMERICA 
             TABLE 211 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 212 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 213 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
             TABLE 214 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
             TABLE 215 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 216 LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.1 BRAZIL
                        11.5.1.1 Growing need for advanced cancer research and therapeutic development to drive market
                                      TABLE 217 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 218 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
                                      TABLE 219 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
                                      TABLE 220 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 221 BRAZIL: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.2 REST OF LATIN AMERICA
                        TABLE 222 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
                        TABLE 223 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
                        TABLE 224 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
                        TABLE 225 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                        TABLE 226 REST OF LATIN AMERICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.5.3 LATIN AMERICA: IMPACT OF RECESSION
     11.6 MIDDLE EAST & AFRICA 
             TABLE 227 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY COUNTRY, 2021–2028 (USD MILLION)
             TABLE 228 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
             TABLE 229 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
             TABLE 230 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
             TABLE 231 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
             TABLE 232 MIDDLE EAST & AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.6.1 MIDDLE EAST
                        11.6.1.1 Growing use to probe treatment strategies aligned with individual patient profiles to drive market
                                      TABLE 233 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 234 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
                                      TABLE 235 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
                                      TABLE 236 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 237 MIDDLE EAST: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.6.2 AFRICA
                        11.6.2.1 Rising incidence of cancer and expanding research infrastructure to drive market
                                      TABLE 238 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TYPE, 2021–2028 (USD MILLION)
                                      TABLE 239 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY IMPLANTATION METHOD, 2021–2028 (USD MILLION)
                                      TABLE 240 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY TUMOR TYPE, 2021–2028 (USD MILLION)
                                      TABLE 241 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY APPLICATION, 2021–2028 (USD MILLION)
                                      TABLE 242 AFRICA: PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET, BY END USER, 2021–2028 (USD MILLION)
             11.6.3 MIDDLE EAST & AFRICA: IMPACT OF RECESSION
 
12 COMPETITIVE LANDSCAPE (Page No. - 192)
     12.1 OVERVIEW 
     12.2 KEY STRATEGIES ADOPTED BY MAJOR PLAYERS 
             FIGURE 25 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: KEY STRATEGIES ADOPTED BY MAJOR PLAYERS
     12.3 REVENUE SHARE ANALYSIS OF TOP FOUR PLAYERS, 2022 
             FIGURE 26 REVENUE SHARE ANALYSIS FOR TOP FOUR COMPANIES, 2022
     12.4 MARKET SHARE ANALYSIS OF TOP FOUR PLAYERS, 2020–2022 
             FIGURE 27 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET SHARE ANALYSIS OF TOP FOUR PLAYERS, 2020–2022
     12.5 COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                        FIGURE 28 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022
     12.6 COMPANY EVALUATION MATRIX FOR STARTUPS/SMALL AND MEDIUM-SIZED ENTERPRISES (SMES), 2022 
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 STARTING BLOCKS
             12.6.3 RESPONSIVE COMPANIES
             12.6.4 DYNAMIC COMPANIES
                        FIGURE 29 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/SMES, 2022
     12.7 COMPETITIVE BENCHMARKING 
             12.7.1 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: LIST OF STARTUPS/SMES
                        TABLE 243 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: LIST OF STARTUPS/SMES
             12.7.2 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
                        TABLE 244 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES
     12.8 COMPETITIVE SCENARIOS AND TRENDS 
             12.8.1 DEALS
                        TABLE 245 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: DEALS, 2021–2023
             12.8.2 OTHERS
                        TABLE 246 PATIENT-DERIVED XENOGRAFT (PDX) MODEL MARKET: OTHERS, 2021–2023
 
13 COMPANY PROFILES (Page No. - 204)
     13.1 KEY PLAYERS 
(Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments)*
             13.1.1 JSR CORPORATION
                        TABLE 247 JSR CORPORATION: COMPANY OVERVIEW
                        FIGURE 30 JSR CORPORATION: COMPANY SNAPSHOT
             13.1.2 WUXI APPTEC
                        TABLE 248 WUXI APPTEC: COMPANY OVERVIEW
                        FIGURE 31 WUXI APPTEC: COMPANY SNAPSHOT
             13.1.3 THE JACKSON LABORATORY
                        TABLE 249 THE JACKSON LABORATORY: COMPANY OVERVIEW
                        FIGURE 32 THE JACKSON LABORATORY: COMPANY SNAPSHOT
             13.1.4 CHARLES RIVER LABORATORIES
                        TABLE 250 CHARLES RIVER LABORATORIES: COMPANY OVERVIEW
                        FIGURE 33 CHARLES RIVER LABORATORIES: COMPANY SNAPSHOT
             13.1.5 TACONIC BIOSCIENCES, INC.
                        TABLE 251 TACONIC BIOSCIENCES, INC.: COMPANY OVERVIEW
             13.1.6 ONCODESIGN PRECISION MEDICINE
                        TABLE 252 ONCODESIGN PRECISION MEDICINE: COMPANY OVERVIEW
                        FIGURE 34 ONCODESIGN PRECISION MEDICINE: COMPANY SNAPSHOT
             13.1.7 INOTIV, INC.
                        TABLE 253 INOTIV, INC.: COMPANY OVERVIEW
                        FIGURE 35 INOTIV, INC.: COMPANY SNAPSHOT
             13.1.8 PHARMATEST SERVICES
                        TABLE 254 PHARMATEST SERVICES: COMPANY OVERVIEW
             13.1.9 HERA BIOLABS
                        TABLE 255 HERA BIOLABS: COMPANY OVERVIEW
             13.1.10 EPO BERLIN-BUCH GMBH
                        TABLE 256 EPO BERLIN-BUCH GMBH: COMPANY OVERVIEW
             13.1.11 XENTECH
                        TABLE 257 XENTECH: COMPANY OVERVIEW
             13.1.12 UROSPHERE
                        TABLE 258 UROSPHERE: COMPANY OVERVIEW
             13.1.13 ALTOGEN LABS
                        TABLE 259 ALTOGEN LABS: COMPANY OVERVIEW
             13.1.14 ABNOVA CORPORATION
                        TABLE 260 ABNOVA CORPORATION: COMPANY OVERVIEW
             13.1.15 GENESIS BIOTECHNOLOGY GROUP
                        TABLE 261 GENESIS BIOTECHNOLOGY GROUP: COMPANY OVERVIEW
*Business Overview, Products/Services/Solutions Offered, MnM View, Key Strengths and Right to Win, Strategic Choices Made, Weaknesses and Competitive Threats, Recent Developments might not be captured in case of unlisted companies.
     13.2 OTHER PLAYERS 
             13.2.1 BIOCYTOGEN PHARMACEUTICALS CO., LTD.
             13.2.2 CREATIVE ANIMODEL
             13.2.3 BIODURO-SUNDIA INC.
             13.2.4 ARAGEN LIFE SCIENCES
             13.2.5 SHANGHAI LIDE BIOTECH CO., LTD.
             13.2.6 CERTIS ONCOLOGY SOLUTIONS
             13.2.7 INNOSER
             13.2.8 IVRS AB
             13.2.9 BEIJING IDMO CO. LTD.
             13.2.10 SHANGHAI CHEM PARTNER CO. LTD.
 
14 APPENDIX (Page No. - 242)
     14.1 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 
     14.2 CUSTOMIZATION OPTIONS 
     14.3 RELATED REPORTS 
     14.4 AUTHOR DETAILS 

This study involved four major activities in estimating the current size of the patient-derived xenograft/ PDX model market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market. The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size. After that, market breakdown and data triangulation procedures were used to estimate the market size of segments.

Secondary Research

Secondary research was used mainly to identify and collect information for the extensive, technical, market-oriented, and commercial study of the patient-derived xenograft/ PDX model market. The secondary sources used for this study include some of the key secondary sources: American Association for Cancer Research, American Association for Laboratory Animal Science, EurOPDX, European Animal Research Association, European Society for Medical Oncology, European Association for Cancer Research, Federation for Laboratory Animal Science Associations, Medical Research Council, Sao Paulo Research Foundation, Centers for Disease Control and Prevention, Food and Drug Administration, Company Websites, Annual Reports, SEC Filings, Press Releases, Investor Presentations, Interviews with Experts, and MarketsandMarkets Analysis. Secondary sources include corporate and regulatory filings (such as annual reports, SEC filings, investor presentations, and financial statements), business magazines and research journals, press releases, and trade, business, and professional associations. These sources were also used to obtain key information about major players, market classification, and segmentation according to industry trends, regional/country-level markets, market developments, and technology perspectives.

Primary Research

In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, among other experts, to obtain and verify the critical qualitative and quantitative information as well as assess the prospects of the market. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information.

Patient-Derived Xenograft/PDX Model Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches were used to estimate and validate the total size of the patient-derived xenograft/ PDX model market. These methods were also used extensively to estimate the size of various subsegments in the market. The research methodology used to estimate the market size includes the following:

  • The key players in the industry and market have been identified through extensive secondary research
  • The revenues generated from the patient-derived xenograft/ PDX model business of leading players have been determined through primary and secondary research.
  • All percentage shares, splits, and breakdowns have been determined using secondary sources and verified through primary sources.

Global patient-derived xenograft/ PDX model Market: Bottom-Up Approach

Patient-Derived Xenograft/PDX Model Market Size, and Share

To know about the assumptions considered for the study, Request for Free Sample Report

Global patient-derived xenograft/ PDX model Market Size: Top-Down Approach

Patient-Derived Xenograft/PDX Model Market Size, and Share

Data Triangulation

After arriving at the overall market size from the market size estimation process, the total market was split into several segments. To complete the overall market engineering process and arrive at the exact statistics for all segments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Market Definition

Patient-derived xenograft (PDX) models are models in which tumor tissues from patients are implanted into immunodeficient mice and rats and have shown superiority in recapitulating the characteristics of cancer, such as the spatial structure of cancer and the intratumor heterogeneity of cancer. Moreover, PDX models retain the genomic features of patients across different stages, subtypes, and diversified treatment backgrounds. The market is driven by the increasing demand for oncology research and precision medicine.

Key Stakeholders

  • Manufacturers and distributors of patient-derived xenograft/ PDX models
  • Pharmaceutical and biotechnology companies
  • Market research and consulting firms
  • R&D centers
  • Researchers and scientists
  • Academic & research institutes

Report Objectives

  • To define, describe, and forecast the patient-derived xenograft/ PDX model market based on type, implantation method, tumor type, application, and end user.
  • To provide detailed information regarding the major factors influencing the growth of the market (such as drivers, restraints, challenges, opportunities, and trends)
  • To strategically analyze micro markets with respect to individual growth trends, future prospects, and contributions to the overall patient-derived xenograft/ PDX model market.
  • To analyze opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
  • To strategically profile the key players and comprehensively analyze their product portfolios, market positions, and core competencies
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, agreements, partnerships, and R&D activities in the patient-derived xenograft/ PDX model market.

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per the company’s specific needs. The following customization options are available for this report:

Company Information

  • Twenty-five company profiles
Custom Market Research Services

We will customize the research for you, in case the report listed above does not meet with your exact requirements. Our custom research will comprehensively cover the business information you require to help you arrive at strategic and profitable business decisions.

Request Customization

Instant Answers with GPT - Ask Now!

Ask real questions. Get complete answers !
Report Code
BT 5576
Published ON
Aug, 2023
Choose License Type
BUY NOW
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Patient-Derived Xenograft/PDX Model Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2024 MarketsandMarkets Research Private Ltd. All rights reserved
DMCA.com Protection Status Website Feedback